The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global continuous glucose monitoring systems market was valued at US$ 5.46 Billion in 2021.
We expect the global continuous glucose monitoring systems market to exhibit a CAGR of 9.50% during 2022-2027.
The sudden outbreak of the COVID-19 pandemic has led to the growing demand for remote monitoring devices, such as continuous glucose monitoring systems to continuously monitor the coronavirus-infected patients with diabetes.
The rising adoption of continuous glucose monitoring systems for measuring glucose and insulin level in the body, as they are non-invasive and provide real-time information, is primarily driving the global continuous glucose monitoring systems market.
Based on the component, the global continuous glucose monitoring systems market can be segmented into sensors, transmitters and receivers, and integrated insulin pumps. Among these, sensors hold the majority of the total market share.
Based on the demographics, the global continuous glucose monitoring systems market has been divided into child population (≤14 years) and adult population (>14 years), where adult population (>14 years) currently exhibits a clear dominance in the market.
Based on the end user, the global continuous glucose monitoring systems market can be categorized into clinics and diagnostics centers, ICUs, and home healthcare. Currently, home healthcare accounts for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global continuous glucose monitoring systems market include A. Menarini Diagnostics S.r.l., Abbott Laboratories, DexCom Inc., F. Hoffmann-La Roche AG, Glysens Incorporated, LifeScan Inc. (Johnson & Johnson), Medtronic PLC, Medtrum Technologies Inc., Nemaura Medical Inc., Novo Nordisk A/S, Senseonics Holdings Inc., and Waveform Technologies Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at